Global ubiquitome analysis of substantia nigra in doubly-mutant human alpha-synuclein transgenic mice
- PMID: 31846630
- DOI: 10.1016/j.bbr.2019.112436
Global ubiquitome analysis of substantia nigra in doubly-mutant human alpha-synuclein transgenic mice
Abstract
Progression through neuronal loss of substantia nigra pars compacta (SNpc) with Parkinson's disease depends on various protein post-translational modifications mainly comprising ubiquitination. Although many ubiquitination sites have been identified through site-specific methods, systematic quantitative proteomic analysis of pre-symptomatic Parkinson's disease remains unexplored. Using quantitative proteomics, we have globally profiled ubiquitination in SNpc tissue of a Parkinson's disease transgenic mouse model (A30P*A53 T α-synuclein, hm2α-SYN-39 mouse strain) at pre-symptomatic stage; Our datasets of 3971 ubiquitination sites in 1595 proteins provide valuable insight into pre-symptomatic Parkinson's disease. Subsequent bioinformatics analysis, including gene ontology analysis, KEGG pathway annotation, functional cluster analysis, and motif analysis were performed to annotate quantifiable targets of ubiquitination sites. Therefore, this elucidation of the dysregulation of ubiquitination has implications for understanding the pathophysiological mechanism of dopaminergic neuron degeneration and for developing novel therapeutics for Parkinson's disease.
Keywords: Alpha-synuclein; Parkinson’s disease; Quantitative proteomics; Ubiquitination.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Quantitative Phosphoproteomic Analysis in Alpha-Synuclein Transgenic Mice Reveals the Involvement of Aberrant p25/Cdk5 Signaling in Early-stage Parkinson's Disease.Cell Mol Neurobiol. 2020 Aug;40(6):897-909. doi: 10.1007/s10571-019-00780-7. Epub 2020 Feb 3. Cell Mol Neurobiol. 2020. PMID: 32016637
-
Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.Int J Mol Sci. 2021 Mar 13;22(6):2939. doi: 10.3390/ijms22062939. Int J Mol Sci. 2021. PMID: 33805843 Free PMC article.
-
Expression signatures of long non-coding RNA in the substantia nigra of pre-symptomatic mouse model of Parkinson's disease.Behav Brain Res. 2017 Jul 28;331:123-130. doi: 10.1016/j.bbr.2017.04.044. Epub 2017 May 2. Behav Brain Res. 2017. PMID: 28476570
-
Uncovering Novel Therapeutic Targets for Parkinson's Disease.ACS Chem Neurosci. 2023 Jun 7;14(11):1935-1949. doi: 10.1021/acschemneuro.3c00084. Epub 2023 May 25. ACS Chem Neurosci. 2023. PMID: 37227448 Review.
-
α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.Neurodegener Dis. 2014;14(1):1-17. doi: 10.1159/000354615. Epub 2013 Sep 24. Neurodegener Dis. 2014. PMID: 24080741 Review.
Cited by
-
Proteome and ubiquitinome analyses of the brain cortex in K18-hACE2 mice infected with SARS-CoV-2.iScience. 2024 Jul 27;27(9):110602. doi: 10.1016/j.isci.2024.110602. eCollection 2024 Sep 20. iScience. 2024. PMID: 39211577 Free PMC article.
-
Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.Cell Death Differ. 2021 Feb;28(2):439-454. doi: 10.1038/s41418-020-00667-x. Epub 2020 Nov 18. Cell Death Differ. 2021. PMID: 33208890 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous